首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1425113

Gabapentin市場 - 預測 2024-2029

Gabapentin Market - Forecasts from 2024 to 2029

出版日期: 2024年01月24日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

Gabapentin市場預計在預測期內複合年成長率為 3.82%。

口服Gabapentin溶液、錠劑和膠囊可與其他藥物合併使用，幫助癲癇患者控制癲癇發作。帶狀皰疹後遺症神經痛(PHN) 的特徵是帶狀皰疹爆發後持續數月至數年的燒灼樣刺痛，可使用Gabapentin膠囊、錠劑和口服溶液治療。Gabapentin噴丁緩釋片（Horizont）用於治療不寧腿症候群（RLS），這是一種導致腿部疼痛和強烈移動慾望的疾病，尤其是在夜間或坐著或躺著時。此外，Gabapentin透過減少過度活躍的大腦活動來治療癲癇發作。

Gabapentin市場促進因素

影響Gabapentin市場成長的主要因素是神經病變疼痛和癲癇發作的發生率增加以及疼痛管理藥物的使用率增加。政府舉措的不斷加強、製藥公司的研發投資以及老年人口的增加是推動Gabapentin市場成長的主要因素。

增加疼痛管理的使用

Gabapentin用於緩解神經不適。普通藥物通常無法緩解這種不適。Gabapentin改變神經與大腦的通訊方式。如果神經受到壓迫或無法正常運作，它就會向大腦發送錯誤訊號。即使你身體的某個部位沒有受傷，你的大腦還是會這樣感知。Gabapentin透過改變神經功能來減輕疼痛。

Gabapentin新劑型的研發

抗驚厥藥物Gabapentin用於治療神經病變疼痛和局部癲癇發作，對Gabapentin市場的成長有正面影響。藥物的藥物動力學特性可以透過使用尼索姆（一種基於脂質的藥物載體）來改善。在這項研究中，我們創建了Gabapentin的囊泡製劑，並評估了最佳囊泡製劑在正常細胞和結腸癌細胞株中的細胞毒性作用。我們創建了許多脂質體製劑並研究了它們的理化性質。 G3 和 G4 製劑的釋放曲線與 Korsmeyer-Peppas 模型密切匹配，顯示Gabapentin釋放存在 Fickian 擴散機制。

擴大在醫療保健和診所的使用

基層醫療醫生、職業中期醫生、神經科、內科醫生和整形外科醫生經常開立Gabapentin來治療各種疾病。除了抗驚厥作用外，這種藥物還有其他用途。護理師透過充當聯絡人、檢查劑量和回答患者詢問來為醫生提供支援。專業團隊的所有成員都知道Gabapentin濫用的可能性。這種專業團隊合作可以最大限度地發揮Gabapentin治療的益處，同時最大限度地減少潛在的副作用。因此，有關Gabapentin用的知識的增加正在推動Gabapentin市場的發展。

標籤仿單標示外治療的使用增加

在醫學領域，特別是在精神病學領域，Gabapentin經常在其核准用途之外使用。美國FDA 已就Gabapentin與中樞神經系統抑制劑 (CNS-D) 合併使用的危險發出警告，加巴噴丁經常被推薦用於精神科治療。該警告的重點是在精神病學中同時使用中樞神經系統抑制劑（CNS-D）和Gabapentin的仿單標示外使用。

在北美，Gabapentin市場預計將穩定成長。

由於該地區神經系統疾病發病率高且以持續性疼痛為特徵的疾病占主導地位，預計北美將佔據Gabapentin市場的最大銷售佔有率。 FDA 支持在這一領域推出學名藥，這將增加該產品在美國的供應。此外，由於藥品意識的提高，亞太地區預計將成為第二大成長產業。

併購

2023 年4 月，GSK plc 和BELLUS Health Inc. 收購了BELLUS，這是一家加拿大後期生物製藥公司，專注於改善難治性慢性咳嗽(RCC) 患者的生活，葛蘭素史克為此支付了每股普通股14.75 美元現金。同意以約 20 億美元（16 億英鎊）的股票收購該公司。
2022年12月，JanOne收購了Soin Therapeutics及其LDN藥物（現稱為JAN123）。 JAN123是一種全新的雙相LDN配方，含有2.0毫克LDN。

When used with other drugs, gabapentin oral solution, pills, and capsules assist individuals with epilepsy in controlling seizures. Additionally, postherpetic neuralgia (PHN), which is characterized by searing, stabbing pain or pains that can last for months or years following an outbreak of shingles, is treated with gabapentin capsules, tablets, and oral solutions. RLS, a disorder that causes pain in the legs and a strong impulse to move the legs, especially at night and when sitting or lying down, is treated with gabapentin extended-release tablets (Horizant). Further, Gabapentin cures seizures by reducing excessive brain activity.

Driving factors for the gabapentin market

The major factor influencing the growth of the gabapentin market is the increasing incidence of neuropathic pain and seizures and the rising utilization of pain management drug. Rise in government initiatives, R&D investments by pharmaceutical companies, and an increasing geriatric population are the key factors fueling the gabapentin market growth.

Increasing use for pain management

The medication gabapentin is used to relieve nerve discomfort. Typical medicines frequently fail to provide relief for this kind of discomfort. Gabapentin alters the way nerves communicate with the brain. A nerve can transmit erroneous signals to the brain when it is compressed or when it isn't functioning correctly in any other manner. Even when a portion of the body is not wounded, the brain perceives it as such. Gabapentin lessens the pain by changing the way nerves function.

Development of new formulations for Gabapentin

Anticonvulsant medication gabapentin is used to treat neuropathic pain and partial seizures and positively impacts the gabapentin market growth. The pharmacokinetic characteristics of medicinal medicines can be enhanced by the use of nisomes, a class of lipid-based drug carriers. In this work, a niosomal formulation of gabapentin was created, and the optimal niosomal formulation's cytotoxicity impact was assessed on normal cells and colon cancer cell lines. Numerous niosomal formulations were created, and the physicochemical characteristics of each were examined. The release profile for the G3 and G4 formulations closely matches the Korsmeyer-Peppas model and suggests the Fickian diffusion mechanism for gabapentin release.

Growing use in healthcare and clinics

Primary care physicians, mid-level practitioners, neurologists, internists, and orthopedic surgeons frequently prescribe gabapentin to treat a variety of medical conditions. In addition to its anti-seizure abilities, the medication has other applications. Nurses assist the physician by serving as a point of contact, reviewing doses, and responding to patient inquiries. The likelihood of gabapentin abuse is known to every member of the interprofessional team. The coordination of an interprofessional team in this way maximizes the benefits of gabapentin therapy while minimizing any possible side effects. This growing knowledge about the utilization is boosting the gabapentin market.

Increasing utilization in off-label medical practices

In medicine, especially psychiatry, gabapentin is frequently administered outside of its approved uses. The United States FDA issued a warning about the dangers of combining the medication gabapentin with central nervous system depressants (CNS-Ds), which are frequently recommended for psychiatric therapy. This focuses on concurrent CNS-D drug usage and off-label outpatient gabapentin use for psychiatric purposes.

In North America, it is projected that the gabapentin market will grow steadily.

North America is anticipated to hold the biggest revenue share in the gabapentin market owing to the high incidence of neurological diseases and ailments characterized by persistent pain in the area may be the reason for the dominance. The FDA is in favor of generic drug launches in the area, which will increase product availability in the United States. Furthermore, Asia Pacific is anticipated to be the second largest growing gabapentin industry, owing to the increase in awareness about the medications.

Merger & Acquisitions

In April 2023, GSK plc and BELLUS Health Inc. reached an agreement under which GSK will acquire BELLUS, a Canadian late-stage biopharmaceutical company that is working to improve the lives of patients with refractory chronic cough (RCC), for US$14.75 per share of common stock in cash, or roughly US$2.0 billion (£1.6 billion) in total equity value.
In December 2022, JanOne purchased Soin Therapeutics and its LDN medication, which is now known as JAN123, under the terms of the Purchase Agreement. JAN123 is a brand-new LDN formulation with a biphasic product release that contains 2.0 mg of LDN.

Market Key Developments

In September 2023, the leading global pharmaceutical company Lotus Pharmaceutical collaborated with the leading B2B pharma player, Adalvo, to announce the introduction of Gabapentin ER 300/600 mg in South Korea.
In March 2023, the pharmaceutical company Granules India Ltd. announced that the US health agency has approved its generic gabapentin pills for use in treating postherpetic neuralgia in adults. According to Granules India in a regulatory filing, the US Food & Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) for gabapentin tablets in the strengths of 600 mg and 800 mg.

Segmentation:

By Type

Generic
Branded

By Application

Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. GABAPENTIN MARKET, BY TYPE

5.1. Introduction
5.2. Generic
5.3. Branded

6. GABAPENTIN MARKET, BY APPLICATION

6.1. Introduction
6.2. Epilepsy
6.3. Neuropathic Pain
6.4. Restless Legs Syndrome
6.5. Others

7. GABAPENTIN MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Others

8. GABAPENTIN MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others